Evidence map›Paper›PMID 33177501›Full record

ArticleNature communications2020

The tumor suppressor microRNA let-7 inhibits human LINE-1 retrotransposition.

Pablo Tristán-Ramos, Alejandro Rubio-Roldan, Guillermo Peris, Laura Sánchez, Suyapa Amador-Cubero, Sebastien Viollet, Gael Cristofari, Sara R Heras

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. LINE-1 Retrotransposons and Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Regulatory Effects ofFood science & nutrition · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Pablo Tristán-RamosGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.ORCID 0000-0001-5368-0466
Alejandro Rubio-RoldanGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.ORCID 0000-0002-6775-4013
Guillermo PerisGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.ORCID 0000-0003-2010-7844
Laura SánchezGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.ORCID 0000-0003-2243-6166
Suyapa Amador-CuberoGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.
Sebastien ViolletUniversité Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.
Gael CristofariUniversité Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.ORCID 0000-0001-5620-3091
Sara R HerasGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain. sara.rodriguez@genyo.es.ORCID 0000-0003-1677-7685
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESCentre National de la Recherche Scientifique · FRUniversidad de Granada · ESUniversitat Jaume I · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nearly half of the human genome is made of transposable elements (TEs) whose activity continues to impact its structure and function. Among them, Long INterspersed Element class 1 (LINE-1 or L1) elements are the only autonomously active TEs in humans. L1s are expressed and mobilized in different cancers, generating mutagenic insertions that could affect tumor malignancy. Tumor suppressor microRNAs are ∼22nt RNAs that post-transcriptionally regulate oncogene expression and are frequently downregulated in cancer. Here we explore whether they also influence L1 mobilization. We show that downregulation of let-7 correlates with accumulation of L1 insertions in human lung cancer. Furthermore, we demonstrate that let-7 binds to the L1 mRNA and impairs the translation of the second L1-encoded protein, ORF2p, reducing its mobilization. Overall, our data reveals that let-7, one of the most relevant microRNAs, maintains somatic genome integrity by restricting L1 retrotransposition.

Indexed as

3' Untranslated RegionsAdenocarcinoma of LungBinding SitesCarcinoma, Squamous CellEndonucleasesGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansLong Interspersed Nucleotide ElementsLung NeoplasmsMicroRNAsProtein BiosynthesisRNA-Directed DNA PolymeraseRNA, MessengerTumor Cells, CulturedWhole Genome Sequencing3' Untranslated RegionsEndonucleasesMicroRNAsmirnlet7 microRNA, humanORF2 protein, humanRNA-Directed DNA PolymeraseRNA, Messenger

Identifiers

PMID33177501
PMCPMC7658363
OpenAlexW3101966582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.